Quality of evidence of anti-obesity pharmacotherapy: an overview of systematic reviews
Rev. ciênc. farm. básica apl
; 3901/01/2018. tab, ilus
Article
in English
| LILACS
| ID: biblio-1100210
Responsible library:
BR33.1
ABSTRACT
The safety and effectiveness of main anti-obesity drugs are controversial, and there is no consensus among regulatory agencies regarding anti-obesity drugs. We undertook an overview of systematic reviews (SR) of randomized controlled trials (RCT) to summarize the quality of evidence related to anti-obesity drugs. Data sources included Medline, Scopus, The Cochrane Library and PROSPERO. Twenty-one SR (564 RCT; average of 2,356 participants per review) satisfied the inclusion criteria. Ten SR presented a high level of heterogeneity, and only five SR included sensitivity analyses. The most important limitations reported by the SR were a high level of attrition, a small sample size, and a short follow-up. Eight different outcomes for efficacy were used, 15 different outcomes for biomarkers were used, and nine different outcomes for safety were used. Conclusions:
In conclusion, the quality of SR pertaining to anti-obesity drugs is low, and these reviews have a high level of heterogeneity. Future SR should present more detailed population inclusion criteria, larger sample sizes, and focus variables reported in a predefined anti-obesity core outcome set.(AU)
Full text:
Available
Collection:
International databases
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 7: Evidence and knowledge in health
Database:
LILACS
Main subject:
Anti-Obesity Agents
/
Evidence-Based Practice
/
Obesity
Type of study:
Controlled clinical trial
/
Overview
/
Systematic review
Limits:
Humans
Language:
English
Journal:
Rev. ciênc. farm. básica apl
Journal subject:
Pharmacology
Year:
2018
Document type:
Article
Affiliation country:
Brazil
/
Portugal
Institution/Affiliation country:
Federal University of Paraná (UFPR)/BR
/
University of Lisbon/PT